scholarly journals Calculated physical and biological results when negatively charged pions are used to irradiate a small and a large ''tumor'' volume in a tissue phantom

1974 ◽  
Author(s):  
R. T. Santoro ◽  
R. G. Alsmiller, Jr.

Background: The typical imaged findings of retinoblastoma are an intraocular tumor with intratumoral calcification. Normal eye size is a supported finding of retinoblastoma. In practice, more than just a few cases had an altered eye size. Objective: To evaluate the effect of eye size in retinoblastoma. Materials and Methods: The present study included 47 patients with 54 diseased eyes. Twenty-seven patients underwent enucleation with histopathological results. The axial lengths (AL) and equatorial diameters (ED) were measured in both diseased and normal eyes. The imaging characteristics, tumor volume, and histopathological findings were recorded and analyzed. Results: The results showed no statistically significant differences between AL, ED, and calculated eye volumes (EV) between diseased and normal eyes. Anterior chamber depths were statistically shallower in retinoblastoma eyes (p<0.001). EV was weakly associated with tumor volumes. Large eye size was significantly related to choroidal invasion, massive choroidal invasion, scleral invasion, and optic nerve invasion in pathology (p=0.04, 0.03, 0.02, and 0.04, respectively). Conclusion: There were no statistically significant differences of eye size parameters in the eyes with retinoblastoma when compared to the normal eyes. Large eye size and large tumor volume are significantly related to invasive histopathological results. Keywords: Retinoblastoma, Intraocular tumor, Eye size, Tumor volume, Histopathology, Neoplasm invasion


2022 ◽  
Author(s):  
Congxiao Wang ◽  
Chao Liu ◽  
Han Jiang ◽  
Wei Zhang ◽  
Lili Yang ◽  
...  

Abstract Background: A more extensive surgical resection of glioma contributes to improved overall survival (OS) and progression-free survival (PFS). However, some of the patients lost the chance of surgical resection when the tumor involves critical structures. Purpose: The present study aimed to assess the feasibility of neoadjuvant 125I brachytherapy followed by total gross resection for initially inoperable glioma.Methods:Six patients diagnosed with inoperable glioma due to invasion of eloquent areas, bi-hemispheric diffusion, or large tumor volume received 125I brachytherapy. Surgical resection was performed when the tumor shrank, allowing a safe resection, assessed by the neurosurgeons. Patients were followed up after surgery.Results:Tumor shrinkage after adjuvant 125I brachytherapy enabled a total gross resection of all six patients. Four patients were still alive at the last follow-up, with the longest survival time of more than 50 months, two of which returned to a normal life with the KPS of 100. Another two patients got a neurological injury with the KPS of 80 and 50, respectively. One patient with grade Ⅱ glioma died 34 months, and another patient with grade Ⅳ glioma died 40 months later after the combined therapy.Conclusions: In the present study, the results demonstrated that 125I brachytherapy enabled a complete resection of patients with initially unresectable gliomas. 125I brachytherapy may offer a proper neoadjuvant therapy method for glioma.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 3632-3632
Author(s):  
Marine Boulesteix ◽  
Mohamed Touati ◽  
Julie Abraham ◽  
Sandrine Verbeke ◽  
Assmae El Badaoui ◽  
...  

Abstract Abstract 3632 Introduction: Although Hodgkin Lymphoma (HL) is highly curable, about 15% of patients (pts) are refractory or relapsed after first line treatment. Classic prognostic scores (e.g. IPS) are useful for identifying high risk pts, who need intensive treatment, and low risk pts, who beneficiate de-escalation to minimize side effects. However, they are not enough suitable to predict outcomes. Consequently, finding new complementary tools for detecting refractory or relapsing pts, remains a challenge. Fluorodeoxyglucose (FDG)-PET/CT involvement in initial staging has been widely studied. Although clinical or CT tumor volume is an important prognostic factor, metabolic tumor volume (MTV) is not enough explored. We performed a study to 1) determine whether MTV and maximum standardized uptake value (SUV) max could be new prognostic markers and 2) compare metabolic tissue heterogeneity with CD68 expression, a promising new prognostic factor linked with inflammatory microenvironment. Patients and methods: Among 456 histologically proven HL pts registered in the Regional Lymphoma database of Limousin (SRRLL, France) since 1990's, 158 have an available sample for CD68 staining. Among the 106 pts who have undergone FDG-PET, 43 pts have available quantitative initial and early response (post-C2) SUV FDG-PET/CT data. The median follow-up was 21 months (6–72.5). Pts were classified following Ann Arbor stages I: 4 pts, II: 17 pts, III: 9 pts, IV: 13 pts. FDG-PET/CT exams were performed with a biograph6 Siemens® device and analyzed with Siemens MI® application. MTV was computed for all pts with a 2D delineation technique and using a thresholding method. The threshold (T) corresponds to mean liver SUV (+3 sd) calculated into 50 cm3 of normal liver. All the tumor voxels (3D pixels) equal or greater than the T belong to MTV. MTV per pathological area (MTVa) was also analyzed. Pts with spleen lesions have an increased volume compared to the others. To minimize spleen's impact, MTV was calculated without spleen (MTVws). Quantitative FDG uptake is routinely measured by SUVmax. The mean SUVmax was also worked out into 1 cm3 around the tumor SUVmax. ROC curves were plotted for continuous variables such as age, erythrocyte sedimentation rate (ESR), MTV, SUVmax and mean SUVmax. CD68, tumor associated macrophage expression, was tested with a 25% threshold for positivity. Significant factors allowed dividing pts into favorable and unfavorable groups. Event free survival (EFS) studies were carried out for all binary variables using COX model. A univariate regression analysis was performed. Variables with a p<0.20 were included in multivariate analysis. Results: Median age and sex ratio (n=43) were respectively 29 y-o (16–77) and 0.87. ROC and univariate analysis showed that MTV, MTVa and MTVws were significant predictors for absence of complete remission (CR) at post-C2 and EFS. Cut-off values for prognosis (Cp) were 310 cm3 for MTV or MTVws and 53 cm3 for MTVa (p<0.001). Cut-off values for post-C2 were 244 cm3 for MTV or MTVws and 62 cm3 for MTVa (p<0.007). For pts with a large tumor volume (MTV, MTVws or MTVa > Cp), 1 and 2 years EFS were shorter (figure1). Two years EFS for MTV, MTVa and MTVws are respectively: 40%, 50% and 21% for large tumor volume and 87%, 86% and 89% for small tumor volume (p= 0.004, p=0.01 and p=0.0003). The mean SUVmax and heterogeneity were significant in univariate analysis (p=0.01 and p=0.04) but not in ROC analysis. Heterogeneity level was not correlated with CD68 expression. Each new parameter was compared, in multivariate analysis, to ESR, stages, B symptoms, bulky, age. MTV was an independent factor for predicting outcomes and post-C2 results (p<0.01) and better than mean SUV max. Similar results were found for MTVa and MTVws (p<0.02 and p<0.01). Discussion: In spite of limited number of pts and short follow-up, prognostic value of MTV is very significant. Those data are in accordance with the few results previously reported (Hutchings et al. Int J Radiat Oncol Biol Phys, 2005). Song et al. (Cancer Science, 2012) also highlighted that MTV was better predictor than SUVmax in DLBCL. Conclusion: Large MTV seems to be a potential predictive marker for adverse post-C2 results and EFS. These data need further studies to confirm, in larger cohort, these first promising results to establish a better initial risk stratification of pts, leading to optimal adaptive therapy strategy. Disclosures: No relevant conflicts of interest to declare.


Author(s):  
Ji-Eun Chang ◽  
Yang Liu ◽  
Woo Kyoung Lee ◽  
Il Yoon ◽  
Kwhanmien Kim

Photodynamic therapy (PDT) with a suitable photosensitizer molecule is a promising anticancer treatment. We evaluated two chlorin molecules as potential photosensitizers, methyl pyropheophorbide a (MPPa) and N-methoxyl purpurinimide (NMPi), against A549 human lung adenocarcinoma cells in vitro as well as in A549 tumor-bearing mice in vivo. Cell viability, microscopy, and FACS analyses were performed for the in vitro studies. MPPa and NMPi showed high phototoxicity in vitro, which was dependent on the concentration of the photosensitizers as well as the light irradiation time. In the animal study, tumor volume change, tumor surface alterations, and H&amp;E and TUNEL staining analyses were performed and compared between small (tumor volume of &lt;50 mm3) and large (tumor volume of &gt;50 mm3) size of initial tumors. MPPa and NMPi showed high anticancer efficacy against small-size tumors, indicating that early treatment with PDT is effective. Especially, repeated two times PDT with NMPi allowed almost complete eradication against small-size tumors. However, MPPa and NMPi were not effective against large-size tumors. In conclusion, the two chlorin derivatives, MPPa and NMPi, show good anticancer efficacy as promising photosensitizers for PDT in vitro and in vivo. Moreover, their activity in vivo was significantly dependent on the initial tumor size in mice, which confirms the importance of early cancer treatment.


2019 ◽  
pp. 1-3
Author(s):  
Bansari Sorathiya

PURPOSE: To study clinical characteristics of Retinoblastoma and analyze the occurrences of patient survival and globe salvation. METHODS: This is a prospective and non-randomized study involving retinoblastoma patients at a tertiary institute from May, 2017 to May, 2019. All patients underwent comprehensive medical assessment and illness management investigations. The given treatment was recorded, including focal therapy, enucleation and chemotherapy. RESULTS: Leukocoria was the foremost common presentation (60.68%) followed by proptosis (12.3%). The patient survival rate was 87.7% whereas globe salvation was at 23.2% (19 eyes). CONCLUSION: Most patients came for clinical examination for rst time at a later stage of disease, having high risk clinical features such as positive family history, hyphema, and large tumor volume. More awareness and early stage diagnosis are of prime importance in order to achieve globe salvation in retinoblastoma.


2019 ◽  
Author(s):  
Ryang-Hun Lee ◽  
Jae Min Kim ◽  
Jin Hwan Cheong ◽  
Je Il Ryu ◽  
Young Soo Kim ◽  
...  

AbstractBackground and purposeDisruption of the tumor-brain barrier in meningioma plays a critical role in the development of peritumoral brain edema (PTBE). We hypothesized that osteoporotic conditions may be associated with PTBE occurrence after radiation in patients with intracranial meningioma.MethodsWe measured Hounsfield units (HU) of the frontal skull on simulation brain CT in patients who underwent linear accelerator (LINAC)-based radiation treatment for intracranial meningioma. Receiver operating characteristic curve analysis was performed to determine the optimal cut-off values for several predictive factors. The cumulative hazard for PTBE was estimated and classified according to these factors. Hazard ratios were then estimated to identify independent predictive factors associated with the development of PTBE after radiation in intracranial meningioma patients.ResultsA total of 83 intracranial meningiomas in 76 patients who received LINAC-based radiation treatment in our hospital over an approximate 5-year period were included for the study. We found mean frontal skull HU ≤630.625 and gross tumor volume >7.194 cc to be independent predictors of PTBE after radiation treatment in patients with meningioma (hazard ratio, 8.38; P=0.021; hazard ratio, 5.78; P=0.034, respectively). In addition, patients who were ≥65 years showed a marginally significant association with PTBE.ConclusionsOur study suggests that possible osteoporotic conditions, large tumor volume, and older age may be associated with PTBE occurrence after LINAC-based radiation treatment for intracranial meningioma. In the future we anticipate that these findings may enhance the understanding of the underlying mechanisms of PTBE after radiation in meningioma patients.


Neurosurgery ◽  
2011 ◽  
Vol 70 (3) ◽  
pp. 639-645 ◽  
Author(s):  
Keith R. Unger ◽  
Christopher E. Lominska ◽  
June Chanyasulkit ◽  
Pamela Randolph-Jackson ◽  
Robert L. White ◽  
...  

Abstract Background: Peritumoral edema is a recognized complication following stereotactic radiosurgery (SRS). Objective: To evaluate the risk of posttreatment peritumoral edema following SRS for intracranial meningiomas and determine predictive factors. Methods: Between 2002 and 2008, 173 evaluable patients underwent CyberKnife or Gamma Knife SRS for meningiomas. Eighty-four patients (49%) had prior surgical resections, 13 patients had World Health Organization grade II (atypical) meningiomas, and 117 patients had a neurological deficit before SRS. Sixty-two tumors were in parasagittal, parafalcine, and convexity locations. The median tumor volume was 4.7 mL (range, 0.1–231.8 mL). The median prescribed dose and median prescribed biologically equivalent dose were 15 Gy (range, 9–40 Gy) and 67 Gy (range, 14–116 Gy), respectively. Ninety-seven patients were treated with single-fraction SRS, 74 received 2 to 5 fractions, and 2 received &gt;5 fractions. Results: The median follow-up was 21.0 months. Thirteen patients (8%) developed symptomatic peritumoral edema, with a median onset time of 4.5 months (range, 0.2– 9.5 months). The 3-, 6-, 12-, and 24-month actuarial symptomatic edema rates were 2.9%, 4.9%, 7.7%, and 8.5%, respectively. The crude tumor control rate was 94%. On univariate analysis, large tumor volume (P = .01) and single-fraction SRS (P = .04) were predictive for development of posttreatment edema. Conclusion: SRS meningioma treatment demonstrated a low incidence of toxicity; however, large tumor volumes and single-fraction SRS treatment had an increased risk for posttreatment edema. Risk factors for edema should be considered in meningiomas treatment.


Sign in / Sign up

Export Citation Format

Share Document